# Myeloproliferative Neoplasms: Diagnosis and Treatment **Type:** Topics **Canonical URL:** https://scholariq.org/topics/myeloproliferative-neoplasms-diagnosis-and-treatment/ ## Facts | Field | Value | | --- | --- | | Description | This cluster of papers focuses on the molecular pathogenesis, diagnosis, treatment, and prognosis of myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, and myelofibrosis. It covers topics such as JAK2 and CALR mutations, prognostic scoring systems, ruxolitinib therapy, hematologic response, leukemic transformation, and stem cell transplantation. | | Domain | Health Sciences | | Field | Medicine | | OpenAlex ID | t11628 | | Works | 121 | ## Topic papers all Showing 15 of 121. - [Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence](https://scholariq.org/papers/clonal-hematopoiesis-and-blood-cancer-risk-inferred-from-blood-dna-sequence/) - [Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease](https://scholariq.org/papers/correction-of-anemia-with-epoetin-alfa-in-chronic-kidney-disease/) - [Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals](https://scholariq.org/papers/redefining-endothelial-progenitor-cells-via-clonal-analysis-and-hematopoietic/) - [Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)](https://scholariq.org/papers/hydroxycarbamide-in-very-young-children-with-sickle-cell-anaemia-a-multicentre/) - [Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia](https://scholariq.org/papers/spectrum-and-prognostic-relevance-of-driver-gene-mutations-in-acute-myeloid/) - [Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.](https://scholariq.org/papers/safety-of-hydroxyurea-in-children-with-sickle-cell-anemia-results-of-the-hug/) - [Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells](https://scholariq.org/papers/physiological-jak2v617f-expression-causes-a-lethal-myeloproliferative-neoplasm/) - [Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms](https://scholariq.org/papers/gain-of-function-of-mutated-c-cbl-tumour-suppressor-in-myeloid-neoplasms/) - [Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa](https://scholariq.org/papers/hydroxyurea-for-children-with-sickle-cell-anemia-in-sub-saharan-africa/) - [SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis](https://scholariq.org/papers/simplify-1-a-phase-iii-randomized-trial-of-momelotinib-versus-ruxolitinib-in/) - [Sickle cell disease: renal manifestations and mechanisms](https://scholariq.org/papers/sickle-cell-disease-renal-manifestations-and-mechanisms/) - [Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene](https://scholariq.org/papers/embryonic-lethality-and-impairment-of-haematopoiesis-in-mice-heterozygous-for-an/) - [Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation](https://scholariq.org/papers/genetic-abnormalities-in-myelodysplasia-and-secondary-acute-myeloid-leukemia/) - [Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I](https://scholariq.org/papers/efficacy-safety-and-survival-with-ruxolitinib-in-patients-with-myelofibrosis/) - [Hydroxyurea therapy for sickle cell anemia](https://scholariq.org/papers/hydroxyurea-therapy-for-sickle-cell-anemia/) ## Topic primary papers Showing 15 of 39. - [Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells](https://scholariq.org/papers/physiological-jak2v617f-expression-causes-a-lethal-myeloproliferative-neoplasm/) - [SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis](https://scholariq.org/papers/simplify-1-a-phase-iii-randomized-trial-of-momelotinib-versus-ruxolitinib-in/) - [Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I](https://scholariq.org/papers/efficacy-safety-and-survival-with-ruxolitinib-in-patients-with-myelofibrosis/) - [Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders](https://scholariq.org/papers/somatic-mutations-of-jak2-exon-12-in-patients-with-jak2-v617f-negative/) - [Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target](https://scholariq.org/papers/gli1-mesenchymal-stromal-cells-are-a-key-driver-of-bone-marrow-fibrosis-and-an/) - [Outcome of Transplantation for Myelofibrosis](https://scholariq.org/papers/outcome-of-transplantation-for-myelofibrosis/) - [Allogeneic hematopoietic stem cell transplantation for myelofibrosis](https://scholariq.org/papers/allogeneic-hematopoietic-stem-cell-transplantation-for-myelofibrosis/) - [A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis](https://scholariq.org/papers/a-pooled-analysis-of-overall-survival-in-comfort-i-and-comfort-ii-2-randomized/) - [Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms](https://scholariq.org/papers/oncogenic-jak2-sup-v617f-sup-causes-pd-l1-expression-mediating-immune-escape-in/) - [Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F](https://scholariq.org/papers/molecular-pathogenesis-and-therapy-of-polycythemia-induced-in-mice-by-jak2-v617f/) - [Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis](https://scholariq.org/papers/pivotal-contributions-of-megakaryocytes-to-the-biology-of-idiopathic/) - [Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia](https://scholariq.org/papers/hematopoietic-cell-transplantation-as-curative-therapy-for-idiopathic/) - [Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis](https://scholariq.org/papers/leukocytosis-and-thrombosis-in-essential-thrombocythemia-and-polycythemia-vera-a/) - [Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial](https://scholariq.org/papers/ropeginterferon-alfa-2b-versus-phlebotomy-in-low-risk-patients-with/) - [Association of Clonal Hematopoiesis of Indeterminate Potential with Worse Kidney Function and Anemia in Two Cohorts of Patients with Advanced Chronic Kidney Disease](https://scholariq.org/papers/association-of-clonal-hematopoiesis-of-indeterminate-potential-with-worse-kidney/) --- Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.